Cerebellar Mutism Syndrome Study

The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develops the Cerebellar Mutism Syndrome (CMS). Furthermore the purpose is to explore the clinical course and the best treatment of the syndrome.

NCT Number	NCT02300766
Lead Sponsor	Rigshospitalet, Denmark Collaborators: Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Technical University of Denmark, Karolinska University Hospital, Skane University Hospital, University Hospital, Linkoeping, Uppsala University Hospital, Sahlgrenska University Hospital, University Hospital, Umeå, Oslo University Hospital, Trondheim University Hospital, Haukeland University Hospital, University Hospital of North Norway, Helsinki University Central Hospital, Tampere University Hospital, Kuopio University Hospital, Turku University Hospital, Oulu University Hospital, Radboud University Medical Center, Liverpool University Hospitals NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Nottingham University Hospitals NHS Trust, University Hospital Birmingham, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Infirmary of Edinburgh, South Glasgow University Hospitals NHS Trust, University Hospital Tuebingen, Medical University of Vienna, Ospedale Pediatrico Bambin Gesù, Motol University Hospital, University of Leipzig Medical Center, Universitaire Ziekenhuizen KU Leuven, Queen Fabiola Children's University Hospital, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital, Ghent, Hospital De La Citadelle, CHC MontLégia, University Hospital, Antwerp, Hospital Sant Joan de Deu, Vienna University Hospital, Austria
Conditions	Infratentorial Neoplasms, Mutism
Enrollment	2,000 participants
Start Date	2014-10
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-12